[국제]WHO approves emergency use of Janssen vaccine… “continue to use AstraZeneca vaccine”

[앵커]

The World Health Organization WHO has approved the emergency use of the Corona 19 vaccine developed by Janssen.

AstraZeneca vaccine, which has been suspended in some countries due to the risk of developing blood clots, has no causal relationship, and should continue to be used.

Reporter Lee Dong-heon’s report.

[기자]

The COVID-19 vaccine developed by Janssen, a subsidiary of Johnson & Johnson, was named as the fourth vaccine approved by the WHO for emergency use.

The WHO assessed that the Janssen vaccine was shown to be effective in the elderly through clinical trials.

In particular, unlike other vaccines that require 2 vaccinations, the advantage is that immunity is formed with 1 vaccination.

In addition, it must be stored at -20 degrees Celsius, but it is maintained for 3 months even between 2 degrees and 8 degrees Celsius, and the shelf life is 2 years.

WHO expects the Janssen vaccine to help address global vaccine inequality.

[테워드로스 아드하놈 거브러여수스 / WHO 사무총장 : 이 백신이 백신 불평등 해소에 도움이 되길 희망합니다. 코백스가 얀센 백신 5억 회분을 예약했습니다.]

The WHO also stressed that there is no causal relationship between the vaccine and the blood clots for the AstraZeneca vaccine, which has recently been raised at risk for clot formation.

[테워드로스 아드하놈 거브러여수스 / WHO 사무총장 : 유럽의약품청이 백신이 혈전관 관련이 없고 조사 중에도 백신을 사용할 수 있다고 말했다는 점을 밝힙니다.]

The WHO emphasized that some items necessary for vaccine manufacturing, such as glass bottles and plastic filters, are experiencing shortages, and emphasized that countries around the world should not stack these items for stockpiling and eventually disrupt vaccine production.

This is YTN Dongheon Lee.

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]